Medical devices: EUR670mn (US$931mn) in 2011 to EU607mn (US$771mn) in 2012; -9.3% in local currency terms and -17.1% in US dollar terms. Forecast unchanged from Q3 12.
Rayna Kostova provides regulatory affairs and pharmacovigilance services including registration of new medicinal products in EU countries, variation procedures, medical device registrations, biocidal product registration, pricing registrations and reimbursement procedures, pharmacovigilance and medicovigilance services, product complaint management, quality management systems, and good distribution practices. Services involve preparation of documentation, negotiation with local authorities, submissions, and translations for Bulgaria and other EU countries.
This document summarizes the services provided by Medical Device Logistics, a leading logistics company in Israel. Their goal is to improve their strategic partners' business results by offering superior customer service, cost-effective solutions, and devoting 100% of their attention to customer needs. Their services include warehousing, quality control, fully computerized logistics processes, and distribution to meet standard, urgent, and life-saving delivery timelines. They aim to free customers' marketing teams through consignment stock management, automated refill orders, and other logistics outsourcing benefits.
China Pharmaceutical Market : SWOT Analysis, Government policies, Business an...Maria Robert
Purchase a copy of this report @ http://www.lifescienceindustryresearch.com/purchase?rname=17129.
Pharmaceutical Industry in China – Cutting-Edge Analysis of Multinational and Chinese Pharma Companies, Industry Trends, Environment, Regulation, Market Drivers, Restraints, Opportunities & Challenges report presented by Company (e.g., AMOYTOP BIOTECH, BEIJING CONTINENT PHARMACEUTICALS, FUSOGEN, SHANGHAI HUAGUAN BIOCHIP, SIBIONO GENETECH, ABBOTT, ROCHE, PFIZER, GSK, NOVARTIS) & by Therapeutic Area (e.g., Anti-infective, Cancer, Diabetes, Dementia, Depression)
The Greek pharmaceutical market has faced challenges since 2010 due to austerity measures implemented in response to the financial crisis. Public pharmaceutical expenditures were cut substantially between 2009 and 2013 in an effort to reduce costs. Reforms were implemented including price cuts, changes to pricing systems, increased generic drug usage, and other measures. Total sales in the Greek pharmaceutical market declined in value between 2009 and 2014 for hospitals, pharmacies, and total sales. The top 10 pharmaceutical companies, which are mostly large multinational companies, maintained a majority market share between 2010 and 2013. A SWOT analysis identified strengths for these major companies including established brands and distribution, but also weaknesses like limited profit margins and threats from ongoing financial instability and regulatory changes in Greece.
Pharmaceutical pricing in european countries - Valérie Paris - 22-01-15Carlos Betancur Gálvez
Valery Paris, analista senior de Política Sanitaria, División de Salud, de la Organización de Desarrollo y Cooperación Económica (OCDE), ha destacado en su ponencia la importancia de considerar en la asignación de los precios de los medicamentos “los beneficios más allá del sector de la salud”, en referencia al coste de oportunidad y a otras variables económicas de lo que supone la entrada de un medicamento en un determinado mercado. París también ha señalado la dificultad de establecer una política común de asignación de precios en los diferentes países europeos: “Los países no siempre llegan a un acuerdo, por ejemplo, en el grado de innovación de nuevos productos”.
Novartis is a global healthcare company based in Switzerland that provides solutions to address the evolving needs of patients worldwide. Our mission is to discover new ways to improve and extend people’s lives. Our vision is to be a trusted leader in changing the practice of medicine.
Kiriasis Savvas, EIPG Greek Delegate
Presentation at Malta Qualified Persons Association-European Industrial Pharmacists Group-University of Malta joint seminar “The Successes And Challenges Of Today’s Pharmaceutical Industry”, Malta 2008.
Pfizer is a large pharmaceutical company founded in 1849 and headquartered in New York. It has annual sales of $44.4 billion and focuses on areas like cardiovascular, infectious diseases, and oncology. While Pfizer has significant market share and resources, it also faces threats such as expiring patents, increased competition from generics, and a reliance on blockbuster drugs.
Rayna Kostova provides regulatory affairs and pharmacovigilance services including registration of new medicinal products in EU countries, variation procedures, medical device registrations, biocidal product registration, pricing registrations and reimbursement procedures, pharmacovigilance and medicovigilance services, product complaint management, quality management systems, and good distribution practices. Services involve preparation of documentation, negotiation with local authorities, submissions, and translations for Bulgaria and other EU countries.
This document summarizes the services provided by Medical Device Logistics, a leading logistics company in Israel. Their goal is to improve their strategic partners' business results by offering superior customer service, cost-effective solutions, and devoting 100% of their attention to customer needs. Their services include warehousing, quality control, fully computerized logistics processes, and distribution to meet standard, urgent, and life-saving delivery timelines. They aim to free customers' marketing teams through consignment stock management, automated refill orders, and other logistics outsourcing benefits.
China Pharmaceutical Market : SWOT Analysis, Government policies, Business an...Maria Robert
Purchase a copy of this report @ http://www.lifescienceindustryresearch.com/purchase?rname=17129.
Pharmaceutical Industry in China – Cutting-Edge Analysis of Multinational and Chinese Pharma Companies, Industry Trends, Environment, Regulation, Market Drivers, Restraints, Opportunities & Challenges report presented by Company (e.g., AMOYTOP BIOTECH, BEIJING CONTINENT PHARMACEUTICALS, FUSOGEN, SHANGHAI HUAGUAN BIOCHIP, SIBIONO GENETECH, ABBOTT, ROCHE, PFIZER, GSK, NOVARTIS) & by Therapeutic Area (e.g., Anti-infective, Cancer, Diabetes, Dementia, Depression)
The Greek pharmaceutical market has faced challenges since 2010 due to austerity measures implemented in response to the financial crisis. Public pharmaceutical expenditures were cut substantially between 2009 and 2013 in an effort to reduce costs. Reforms were implemented including price cuts, changes to pricing systems, increased generic drug usage, and other measures. Total sales in the Greek pharmaceutical market declined in value between 2009 and 2014 for hospitals, pharmacies, and total sales. The top 10 pharmaceutical companies, which are mostly large multinational companies, maintained a majority market share between 2010 and 2013. A SWOT analysis identified strengths for these major companies including established brands and distribution, but also weaknesses like limited profit margins and threats from ongoing financial instability and regulatory changes in Greece.
Pharmaceutical pricing in european countries - Valérie Paris - 22-01-15Carlos Betancur Gálvez
Valery Paris, analista senior de Política Sanitaria, División de Salud, de la Organización de Desarrollo y Cooperación Económica (OCDE), ha destacado en su ponencia la importancia de considerar en la asignación de los precios de los medicamentos “los beneficios más allá del sector de la salud”, en referencia al coste de oportunidad y a otras variables económicas de lo que supone la entrada de un medicamento en un determinado mercado. París también ha señalado la dificultad de establecer una política común de asignación de precios en los diferentes países europeos: “Los países no siempre llegan a un acuerdo, por ejemplo, en el grado de innovación de nuevos productos”.
Novartis is a global healthcare company based in Switzerland that provides solutions to address the evolving needs of patients worldwide. Our mission is to discover new ways to improve and extend people’s lives. Our vision is to be a trusted leader in changing the practice of medicine.
Kiriasis Savvas, EIPG Greek Delegate
Presentation at Malta Qualified Persons Association-European Industrial Pharmacists Group-University of Malta joint seminar “The Successes And Challenges Of Today’s Pharmaceutical Industry”, Malta 2008.
Pfizer is a large pharmaceutical company founded in 1849 and headquartered in New York. It has annual sales of $44.4 billion and focuses on areas like cardiovascular, infectious diseases, and oncology. While Pfizer has significant market share and resources, it also faces threats such as expiring patents, increased competition from generics, and a reliance on blockbuster drugs.
Uveitis global clinical trials review, h1, 2015Ambikabasa
Product Synopsis
Uveitis Global Clinical Trials Review, H1, 2015 Summary GlobalData's clinical trial report, Uveitis Global Clinical Trials Review, H1, 2015" provides an overview of Uveitis clinical trials scenario. This report provides top line data relating to the clinical trials on Uveitis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Global Data Clinical Trial Reports are generated using Global Datas proprietary database - Pharma eTrack Clinical trials database.
http://www.researchmoz.us/uveitis-global-clinical-trials-review-h1-2015-report.html
Cleco corporation power plants and swot analysis, 2015 updateAmbikabasa
This document provides a summary of Cleco Corporation, including its power generation operations, business strategy, and SWOT analysis. It details Cleco's major power plants and assets, operational metrics, products and services, and executives. The report aims to help with business decisions like M&A and understanding competitors, by analyzing Cleco's strategy, structure, and strengths/weaknesses.
Philippines telecoms, mobile and broadbandAmbikabasa
This report provides a comprehensive overview of trends and developments in the Philippines’ telecommunications and digital media market. The report analyses the mobile, internet, broadband, digital TV and converging media sectors. Subjects covered include:
Market and industry analyses, trends and developments;
Facts, figures and statistics;
Industry and regulatory issues;
Infrastructure;
Major players, revenues, subscribers, ARPU;
Internet, VoIP, IPTV;
Mobile voice and data markets;
Broadband (FttH, DSL, wireless);
http://www.researchmoz.us/enquiry.php?type=sample&repid=289037
This report provides comprehensive information on the therapeutic development for Addiction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Addiction and special features on late-stage and discontinued projects.
http://www.researchmoz.us/addiction-pipeline-review-h1-2015-report.html
Arrhythmias - Pipeline Review, H1 2015 Summary Global Markets Directs, Arrhythmias - Pipeline Review, H1 2015, provides an overview of the Arrhythmiass therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Arrhythmias, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Arrhythmias and special features on late-stage and discontinued projects.
http://www.researchmoz.us/arrhythmias-pipeline-review-h1-2015-report.html
This report provides comprehensive information on the therapeutic development for Ocular Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ocular Pain and special features on late-stage and discontinued projects.
http://www.researchmoz.us/ocular-pain-pipeline-review-h1-2015-report.html
The document provides an overview of the global therapeutic pipeline for Paroxysmal Nocturnal Hemoglobinuria (PNH) as of the first half of 2015. It details over 20 drugs in development for PNH across multiple companies and stages of development. The pipeline is evaluated based on drug targets, mechanisms of action, routes of administration, molecule types, and comparative analyses. Recent clinical trial results and developments are also summarized.
This report provides comprehensive information on the therapeutic development for Rhabdomyosarcoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Rhabdomyosarcoma and special features on late-stage and discontinued projects.
http://www.researchmoz.us/rhabdomyosarcoma-pipeline-review-h1-2015-report.html
This report provides comprehensive information on the therapeutic development for Raynauds Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Raynauds Disease and special features on late-stage and discontinued projects.
http://www.researchmoz.us/raynauds-disease-pipeline-review-h1-2015-report.html
The document provides an overview of the therapeutic pipeline for travelers diarrhea as of the first half of 2015. It details over 20 companies and universities developing treatments across various stages. Key late stage products include rifamycin SV MMX and prulifloxacin. The report analyzes the pipeline by target, mechanism of action, route of administration, and molecule type. It provides profiles for the major pipeline products along with recent updates and featured news stories on developments.
This report provides comprehensive information on the therapeutic development for Herpes Zoster (Shingles), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Herpes Zoster (Shingles) and special features on late-stage and discontinued projects.
http://www.researchmoz.us/herpes-zoster-shingles-pipeline-review-h1-2015-report.html
This report provides comprehensive information on the therapeutic development for Emphysema, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Emphysema and special features on late-stage and discontinued projects.
http://www.researchmoz.us/emphysema-pipeline-review-h1-2015-report.html
This report provides comprehensive information on the therapeutic development for Cerebral Infarction (Brain Infarction), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cerebral Infarction (Brain Infarction) and special features on late-stage and discontinued projects.
http://www.researchmoz.us/cerebral-infarction-brain-infarction-pipeline-review-h1-2015-report.html
This report provides comprehensive information on the therapeutic development for Seborrhea, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Seborrhea and special features on late-stage and discontinued projects.
http://www.researchmoz.us/seborrhea-pipeline-review-h1-2015-report.html
This report provides comprehensive information on the therapeutic development for Respiratory Depression, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Respiratory Depression and special features on late-stage and discontinued projects.
http://www.researchmoz.us/respiratory-depression-pipeline-review-h1-2015-report.html
This document reviews the global therapeutic pipeline for H1N1 infection as of the first half of 2015. It provides an overview of pipeline products under development by companies and universities/research institutes. A total of over 20 companies and institutions are developing various drugs, vaccines, and other therapies targeting H1N1. These include both clinical stage products as well as earlier stage programs. The report analyzes the pipeline based on factors such as target, mechanism of action, route of administration, and molecule type.
This report provides comprehensive information on the therapeutic development for Nicotine Addiction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Nicotine Addiction and special features on late-stage and discontinued projects.
http://www.researchmoz.us/nicotine-addiction-pipeline-review-h1-2015-report.html
This report provides comprehensive information on the therapeutic development for Food Allergy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Food Allergy and special features on late-stage and discontinued projects.
http://www.researchmoz.us/food-allergy-pipeline-review-h1-2015-report.html
The document provides an overview of the global therapeutic pipeline for uveal melanoma as of the first half of 2015. It details the various drugs and therapies under investigation by companies and research institutions to treat uveal melanoma. Key players in this field are identified and individual drug profiles are included summarizing each treatment's description, mechanism of action, and development progress. The report aims to help decision making and research strategies regarding uveal melanoma therapeutic development.
Tillotts pharma ag product pipeline review - 2015Ambikabasa
This report provides comprehensive information on the current therapeutic developmental pipeline of Tillotts Pharma AGs, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.
http://www.researchmoz.us/tillotts-pharma-ag-product-pipeline-review-2015-report.html
Uveitis global clinical trials review, h1, 2015Ambikabasa
Product Synopsis
Uveitis Global Clinical Trials Review, H1, 2015 Summary GlobalData's clinical trial report, Uveitis Global Clinical Trials Review, H1, 2015" provides an overview of Uveitis clinical trials scenario. This report provides top line data relating to the clinical trials on Uveitis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Global Data Clinical Trial Reports are generated using Global Datas proprietary database - Pharma eTrack Clinical trials database.
http://www.researchmoz.us/uveitis-global-clinical-trials-review-h1-2015-report.html
Cleco corporation power plants and swot analysis, 2015 updateAmbikabasa
This document provides a summary of Cleco Corporation, including its power generation operations, business strategy, and SWOT analysis. It details Cleco's major power plants and assets, operational metrics, products and services, and executives. The report aims to help with business decisions like M&A and understanding competitors, by analyzing Cleco's strategy, structure, and strengths/weaknesses.
Philippines telecoms, mobile and broadbandAmbikabasa
This report provides a comprehensive overview of trends and developments in the Philippines’ telecommunications and digital media market. The report analyses the mobile, internet, broadband, digital TV and converging media sectors. Subjects covered include:
Market and industry analyses, trends and developments;
Facts, figures and statistics;
Industry and regulatory issues;
Infrastructure;
Major players, revenues, subscribers, ARPU;
Internet, VoIP, IPTV;
Mobile voice and data markets;
Broadband (FttH, DSL, wireless);
http://www.researchmoz.us/enquiry.php?type=sample&repid=289037
This report provides comprehensive information on the therapeutic development for Addiction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Addiction and special features on late-stage and discontinued projects.
http://www.researchmoz.us/addiction-pipeline-review-h1-2015-report.html
Arrhythmias - Pipeline Review, H1 2015 Summary Global Markets Directs, Arrhythmias - Pipeline Review, H1 2015, provides an overview of the Arrhythmiass therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Arrhythmias, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Arrhythmias and special features on late-stage and discontinued projects.
http://www.researchmoz.us/arrhythmias-pipeline-review-h1-2015-report.html
This report provides comprehensive information on the therapeutic development for Ocular Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ocular Pain and special features on late-stage and discontinued projects.
http://www.researchmoz.us/ocular-pain-pipeline-review-h1-2015-report.html
The document provides an overview of the global therapeutic pipeline for Paroxysmal Nocturnal Hemoglobinuria (PNH) as of the first half of 2015. It details over 20 drugs in development for PNH across multiple companies and stages of development. The pipeline is evaluated based on drug targets, mechanisms of action, routes of administration, molecule types, and comparative analyses. Recent clinical trial results and developments are also summarized.
This report provides comprehensive information on the therapeutic development for Rhabdomyosarcoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Rhabdomyosarcoma and special features on late-stage and discontinued projects.
http://www.researchmoz.us/rhabdomyosarcoma-pipeline-review-h1-2015-report.html
This report provides comprehensive information on the therapeutic development for Raynauds Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Raynauds Disease and special features on late-stage and discontinued projects.
http://www.researchmoz.us/raynauds-disease-pipeline-review-h1-2015-report.html
The document provides an overview of the therapeutic pipeline for travelers diarrhea as of the first half of 2015. It details over 20 companies and universities developing treatments across various stages. Key late stage products include rifamycin SV MMX and prulifloxacin. The report analyzes the pipeline by target, mechanism of action, route of administration, and molecule type. It provides profiles for the major pipeline products along with recent updates and featured news stories on developments.
This report provides comprehensive information on the therapeutic development for Herpes Zoster (Shingles), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Herpes Zoster (Shingles) and special features on late-stage and discontinued projects.
http://www.researchmoz.us/herpes-zoster-shingles-pipeline-review-h1-2015-report.html
This report provides comprehensive information on the therapeutic development for Emphysema, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Emphysema and special features on late-stage and discontinued projects.
http://www.researchmoz.us/emphysema-pipeline-review-h1-2015-report.html
This report provides comprehensive information on the therapeutic development for Cerebral Infarction (Brain Infarction), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cerebral Infarction (Brain Infarction) and special features on late-stage and discontinued projects.
http://www.researchmoz.us/cerebral-infarction-brain-infarction-pipeline-review-h1-2015-report.html
This report provides comprehensive information on the therapeutic development for Seborrhea, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Seborrhea and special features on late-stage and discontinued projects.
http://www.researchmoz.us/seborrhea-pipeline-review-h1-2015-report.html
This report provides comprehensive information on the therapeutic development for Respiratory Depression, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Respiratory Depression and special features on late-stage and discontinued projects.
http://www.researchmoz.us/respiratory-depression-pipeline-review-h1-2015-report.html
This document reviews the global therapeutic pipeline for H1N1 infection as of the first half of 2015. It provides an overview of pipeline products under development by companies and universities/research institutes. A total of over 20 companies and institutions are developing various drugs, vaccines, and other therapies targeting H1N1. These include both clinical stage products as well as earlier stage programs. The report analyzes the pipeline based on factors such as target, mechanism of action, route of administration, and molecule type.
This report provides comprehensive information on the therapeutic development for Nicotine Addiction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Nicotine Addiction and special features on late-stage and discontinued projects.
http://www.researchmoz.us/nicotine-addiction-pipeline-review-h1-2015-report.html
This report provides comprehensive information on the therapeutic development for Food Allergy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Food Allergy and special features on late-stage and discontinued projects.
http://www.researchmoz.us/food-allergy-pipeline-review-h1-2015-report.html
The document provides an overview of the global therapeutic pipeline for uveal melanoma as of the first half of 2015. It details the various drugs and therapies under investigation by companies and research institutions to treat uveal melanoma. Key players in this field are identified and individual drug profiles are included summarizing each treatment's description, mechanism of action, and development progress. The report aims to help decision making and research strategies regarding uveal melanoma therapeutic development.
Tillotts pharma ag product pipeline review - 2015Ambikabasa
This report provides comprehensive information on the current therapeutic developmental pipeline of Tillotts Pharma AGs, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.
http://www.researchmoz.us/tillotts-pharma-ag-product-pipeline-review-2015-report.html
L'indice de performance des ports à conteneurs de l'année 2023SPATPortToamasina
Une évaluation comparable de la performance basée sur le temps d'escale des navires
L'objectif de l'ICPP est d'identifier les domaines d'amélioration qui peuvent en fin de compte bénéficier à toutes les parties concernées, des compagnies maritimes aux gouvernements nationaux en passant par les consommateurs. Il est conçu pour servir de point de référence aux principaux acteurs de l'économie mondiale, notamment les autorités et les opérateurs portuaires, les gouvernements nationaux, les organisations supranationales, les agences de développement, les divers intérêts maritimes et d'autres acteurs publics et privés du commerce, de la logistique et des services de la chaîne d'approvisionnement.
Le développement de l'ICPP repose sur le temps total passé par les porte-conteneurs dans les ports, de la manière expliquée dans les sections suivantes du rapport, et comme dans les itérations précédentes de l'ICPP. Cette quatrième itération utilise des données pour l'année civile complète 2023. Elle poursuit le changement introduit l'année dernière en n'incluant que les ports qui ont eu un minimum de 24 escales valides au cours de la période de 12 mois de l'étude. Le nombre de ports inclus dans l'ICPP 2023 est de 405.
Comme dans les éditions précédentes de l'ICPP, la production du classement fait appel à deux approches méthodologiques différentes : une approche administrative, ou technique, une méthodologie pragmatique reflétant les connaissances et le jugement des experts ; et une approche statistique, utilisant l'analyse factorielle (AF), ou plus précisément la factorisation matricielle. L'utilisation de ces deux approches vise à garantir que le classement des performances des ports à conteneurs reflète le plus fidèlement possible les performances réelles des ports, tout en étant statistiquement robuste.
Presentation by Herman Kienhuis (Curiosity VC) on Investing in AI for ABS Alu...Herman Kienhuis
Presentation by Herman Kienhuis (Curiosity VC) on developments in AI, the venture capital investment landscape and Curiosity VC's approach to investing, at the alumni event of Amsterdam Business School (University of Amsterdam) on June 13, 2024 in Amsterdam.
Discover the Beauty and Functionality of The Expert Remodeling Serviceobriengroupinc04
Unlock your kitchen's true potential with expert remodeling services from O'Brien Group Inc. Transform your space into a functional, modern, and luxurious haven with their experienced professionals. From layout reconfiguration to high-end upgrades, they deliver stunning results tailored to your style and needs. Visit obriengroupinc.com to elevate your kitchen's beauty and functionality today.
SATTA MATKA DPBOSS KALYAN MATKA RESULTS KALYAN CHART KALYAN MATKA MATKA RESULT KALYAN MATKA TIPS SATTA MATKA MATKA COM MATKA PANA JODI TODAY BATTA SATKA MATKA PATTI JODI NUMBER MATKA RESULTS MATKA CHART MATKA JODI SATTA COM INDIA SATTA MATKA MATKA TIPS MATKA WAPKA ALL MATKA RESULT LIVE ONLINE MATKA RESULT KALYAN MATKA RESULT DPBOSS MATKA 143 MAIN MATKA KALYAN MATKA RESULTS KALYAN CHART
SATTA MATKA DPBOSS KALYAN MATKA RESULTS KALYAN MATKA MATKA RESULT KALYAN MATKA TIPS SATTA MATKA MATKA COM MATKA PANA JODI TODAY BATTA SATKA MATKA PATTI JODI NUMBER MATKA RESULTS MATKA CHART MATKA JODI SATTA COM INDIA SATTA MATKA MATKA TIPS MATKA WAPKA ALL MATKA RESULT LIVE ONLINE MATKA RESULT KALYAN MATKA RESULT DPBOSS MATKA 143 MAIN MATKA KALYAN MATKA RESULTS KALYAN CHART KALYAN CHART
NIMA2024 | De toegevoegde waarde van DEI en ESG in campagnes | Nathalie Lam |...BBPMedia1
Nathalie zal delen hoe DEI en ESG een fundamentele rol kunnen spelen in je merkstrategie en je de juiste aansluiting kan creëren met je doelgroep. Door middel van voorbeelden en simpele handvatten toont ze hoe dit in jouw organisatie toegepast kan worden.
Prescriptive analytics BA4206 Anna University PPTFreelance
Business analysis - Prescriptive analytics Introduction to Prescriptive analytics
Prescriptive Modeling
Non Linear Optimization
Demonstrating Business Performance Improvement
SATTA MATKA DPBOSS KALYAN MATKA RESULTS KALYAN CHART KALYAN MATKA MATKA RESULT KALYAN MATKA TIPS SATTA MATKA MATKA COM MATKA PANA JODI TODAY BATTA SATKA MATKA PATTI JODI NUMBER MATKA RESULTS MATKA CHART MATKA JODI SATTA COM INDIA SATTA MATKA MATKA TIPS MATKA WAPKA ALL MATKA RESULT LIVE ONLINE MATKA RESULT KALYAN MATKA RESULT DPBOSS MATKA 143 MAIN MATKA KALYAN MATKA RESULTS KALYAN CHART
High-Quality IPTV Monthly Subscription for $15advik4387
Experience high-quality entertainment with our IPTV monthly subscription for just $15. Access a vast array of live TV channels, movies, and on-demand shows with crystal-clear streaming. Our reliable service ensures smooth, uninterrupted viewing at an unbeatable price. Perfect for those seeking premium content without breaking the bank. Start streaming today!
https://rb.gy/f409dk
SATTA MATKA DPBOSS KALYAN MATKA RESULTS KALYAN CHART KALYAN MATKA MATKA RESULT KALYAN MATKA TIPS SATTA MATKA MATKA COM MATKA PANA JODI TODAY BATTA SATKA MATKA PATTI JODI NUMBER MATKA RESULTS MATKA CHART MATKA JODI SATTA COM INDIA SATTA MATKA MATKA TIPS MATKA WAPKA ALL MATKA RESULT LIVE ONLINE MATKA RESULT KALYAN MATKA RESULT DPBOSS MATKA 143 MAIN MATKA KALYAN MATKA RESULTS KALYAN CHART
1. The Pharmaceutical Market: Greece
THE PHARMACEUTICAL MARKET: GREECE - REVIEW
The immediate threat of a Greek default and eurozone exit was reduced as the outcome of the legislative elections in June had a much more benign outcome than
many feared. A n exit would have - and could still be - disastrous for drugmakers operating in the market. But even Greece staying in the monetary union means
the government must continue with its austerity programme. While we continue to hold to our view that Germany and the rest of the EU may reduce the focus on
austerity and introduce some pro-growth strategies, these are unlikely to generate any upside for the pharmaceutical industry and structural reforms within Greece
will be maintained. T he government remains committed to huge cuts in its public drug expenditure for 2012, with a painful claw-back tax in operation and no
extra resources available to pay-back existing debts.
Headline Expenditure Projections
Pharmaceuticals: EUR6.72bn (US$9.35bn) in 2011 to EUR5.92bn (US$7.52bn) in 2012; -12.0% in local currency terms and -19.6% in US dollar terms. Forecast
broadly maintained from Q3 12.
Healthcare: EUR21.80bn (US$30.31bn) in 2011 to EUR20.34bn (US$25.83bn) in 2012; -6.7% in local currency terms and -14.8% in US dollar terms. Forecast
broadly stable from Q3 12.
Medical devices: EUR670mn (US$931mn) in 2011 to EU607mn (US$771mn) in 2012; -9.3% in local currency terms and -17.1% in US dollar terms. Forecast
unchanged from Q3 12.
Risk/RewardRating
In our latest RRRs, we have revised down our assessment of the Greek market, with a downgrade to the industry risk score as a result of broadly unfavourable
operating conditions worsening, specifically re-payment terms, which we have criticised previously, and our assessment of whether innovative drugmakers would
want to launch new products on the market.
Competitive Landscape
The competitive landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical
sector, as well as the OTC, generics, and distribution sub-sectors.
table Of Contents
bmi Industry View 7
swot 10
political 12
economic 13
business Environment 14
industry Forecast 15
pharmaceutical Market Forecast 15
table: Greece Pharmaceutical Sales, Historical Data And Forecasts 18
healthcare Market Forecast 19
table: Healthcare Expenditure Trends, Historical Data And Forecasts, 2009-2017 20
table: Healthcare Governmental Indicators, 2009-2017 20
table: Healthcare Private Indicators, 2009-2017 21
economic Analysis 21
table: Economic Activity 25
prescription Drugs Market Forecast 26
table: Prescription Drug Sales Indicators, 2009-2017 27
patented Drugs Market Forecast 28
table: Patented Drug Sales, 2009-2017 29
The Pharmaceutical Market: Greece
2. generic Drugs Market Forecast 30
table: Generic Drug Sales, 2009-2017 31
otc Medicine Market Forecast 32
table: Otc Medicine Sales, 2009-2017 33
table: Otc Medicine Sales Breakdown, 2007-2010 33
pharmaceutical Trade Forecast 34
table: Pharmaceutical Trade Forecast, 2009-2017 35
key Risks To Bmi's Forecast Scenario 36
industry Risk Reward Ratings 37
table: Central And Eastern Europe Pharmaceutical Risk/reward Ratings, Q213 37
rewards 38
risks 39
market Overview 41
industry Trends And Developments 44
epidemiology 44
healthcare Sector 45
infrastructure 49
table: Inpatient Facilities And Beds By Speciality, 2008 49
table: Outpatient Facilities And Beds By Region, 2008 50
drug Retailing 51
table: Pharmacies By Region, 2007-2009 51
regulatory Development 52
regulatory Regime 52
intellectual Property Regime 53
pricing Regime 53
table: Quarterly Total Sales Volume Per Medicinal Product (additional To 9% Of The Current Decision Rebate Amount) 55
reimbursement Regime 58
competitive Landscape 61
The Pharmaceutical Market: Greece
3. company Profile 63
abbott Laboratories 63
alapis Pharma 65
elpen 68
genesis Pharma 70
glaxosmithkline 72
kleva 74
lavipharm 76
merck Sharpe & Dohme 78
novartis 80
sanofi 82
pfizer 84
pharmathen 86
vianex 88
demographic Forecast 90
table: Greece's Population By Age Group, 1990-2020 ('000) 91
table: Greece's Population By Age Group, 1990-2020 (% Of Total) 92
table: Greece's Key Population Ratios, 1990-2020 93
table: Greece's Rural And Urban Population, 1990-2020 93
methodology 94
methodology 94
risk/reward Ratings Methodology 94
ratings Overview 95
table: Pharmaceutical Business Environment Indicators 95
weighting 96
table: Weighting Of Components 96
sources 96
The Pharmaceutical Market: Greece
4. glossary 97
ResearchMoz(http://www.researchmoz.us/) is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your
research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and
across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an
informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.
Contact:
M/s Sheela,
90 State Street,
Suite 700,
Albany NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free 866-997-4948
Email: sales@researchmoz.us
Website: http://www.researchmoz.us/
The Pharmaceutical Market: Greece